Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Taiho Oncology Drug Patent Portfolio

Taiho Oncology's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Taiho Oncology:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) Taiho Oncology, Inc. NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement Taiho Oncology, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE2
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Taiho Oncology, Inc. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection Taiho Oncology, Inc. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) Taiho Oncology, Inc. NA ENROLLING BY INVITATION
(Jul 1, 2026)
PHASE2
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) Taiho Oncology, Inc. NA TERMINATED
(Jul 1, 2026)
PHASE1
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) Taiho Oncology, Inc. NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. Taiho Oncology, Inc. NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment Taiho Oncology, Inc. NA RECRUITING
(May 1, 2026)
PHASE1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment Taiho Oncology, Inc. NA RECRUITING
(May 1, 2026)
PHASE1
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS Taiho Oncology, Inc. NA COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) Taiho Oncology, Inc. NA RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List